Zentalis Pharmaceuticals (ZNTL) Accumulated Expenses (2022 - 2025)
Historic Accumulated Expenses for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $30.1 million.
- Zentalis Pharmaceuticals' Accumulated Expenses fell 3543.22% to $30.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 3543.22%. This contributed to the annual value of $45.3 million for FY2024, which is 1681.45% down from last year.
- According to the latest figures from Q3 2025, Zentalis Pharmaceuticals' Accumulated Expenses is $30.1 million, which was down 3543.22% from $35.3 million recorded in Q2 2025.
- Zentalis Pharmaceuticals' Accumulated Expenses' 5-year high stood at $54.4 million during Q4 2023, with a 5-year trough of $30.1 million in Q3 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' median Accumulated Expenses value was $44.2 million (recorded in 2022), while the average stood at $41.9 million.
- As far as peak fluctuations go, Zentalis Pharmaceuticals' Accumulated Expenses surged by 4359.21% in 2023, and later crashed by 3543.22% in 2025.
- Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Accumulated Expenses stood at $45.4 million in 2022, then increased by 19.91% to $54.4 million in 2023, then decreased by 16.81% to $45.3 million in 2024, then plummeted by 33.45% to $30.1 million in 2025.
- Its Accumulated Expenses was $30.1 million in Q3 2025, compared to $35.3 million in Q2 2025 and $41.7 million in Q1 2025.